Oncogenic KRAS, Mucin 4, and Activin A-Mediated Fibroblast Activation Cooperate for PanIN Initiation

Adv Sci (Weinh). 2023 Dec;10(36):e2301240. doi: 10.1002/advs.202301240. Epub 2023 Nov 14.

Abstract

Over 90% of patients with pancreatic ductal adenocarcinoma (PDAC) have oncogenic KRAS mutations. Nevertheless, mutated KRAS alone is insufficient to initiate pancreatic intraepithelial neoplasia (PanIN), the precursor of PDAC. The identities of the other factors/events required to drive PanIN formation remain elusive. Here, optic-clear 3D histology is used to analyze entire pancreases of 2-week-old Pdx1-Cre; LSL-KrasG12D/+ (KC) mice to detect the earliest emergence of PanIN and observed that the occurrence is independent of physical location. Instead, it is found that the earliest PanINs overexpress Muc4 and associate with αSMA+ fibroblasts in both transgenic mice and human specimens. Mechanistically, KrasG12D/+ pancreatic cells upregulate Muc4 through genetic alterations to increase proliferation and fibroblast recruitments via Activin A secretion and consequently enhance cell transformation for PanIN formation. Inhibition of Activin A signaling using Follistatin (FST) diminishes early PanIN-associated fibroblast recruitment, effectively curtailing PanIN initiation and growth in KC mice. These findings emphasize the vital role of interactions between oncogenic KrasG12D/+ -driven genetic alterations and induced microenvironmental changes in PanIN initiation, suggesting potential avenues for early PDAC diagnostic and management approaches.

Keywords: Kras; Muc4; PanIN; activin A; αSMA+ fibroblast.

MeSH terms

  • Animals
  • Carcinoma in Situ* / genetics
  • Carcinoma in Situ* / pathology
  • Carcinoma, Pancreatic Ductal* / genetics
  • Humans
  • Mice
  • Mice, Transgenic
  • Mucin-4
  • Pancreatic Neoplasms* / genetics
  • Proto-Oncogene Proteins p21(ras) / genetics

Substances

  • activin A
  • Proto-Oncogene Proteins p21(ras)
  • Mucin-4
  • KRAS protein, human